Rillieux La Pape

Researchers are evaluating the role of hospital pharmacists at the start of oral cancer treatments taken at home. This study aims to see how pharmaceutical monitoring at treatment initiation affects patient adherence, management of side effects, and overall treatment follow-up. The focus is on patients with solid tumors who begin oral therapy for cancer, excluding blood cancers. Participants are randomly assigned to one of two groups one receiving a specialized pharmaceutical consultation at the hospital plus follow-up communication between hospital and community pharmacists, and the other receiving only the initial pharmaceutical consultation. The follow-up includes contacting the patients local pharmacy to ensure treatment continuity and monitoring for issues such as missed refills or side effects. This approach compares standard pharmaceutical consultation with enhanced monitoring and coordination. During the study, patients will be assessed for treatment adherence at 3 and 6 months using the Girerd questionnaire. Researchers will track side effect management and treatment continuation through records kept by the pharmacists. The study emphasizes collaboration between hospital and community pharmacies to support patients throughout their oral cancer therapy. Participation involves regular monitoring and follow-up over several months to evaluate compliance and optimize care.

This research evaluates the Lync4 device implanted in the toes to treat arthritis and correct bone misalignments such as mallet toes, claw toes, and hammer toes. The study aims to confirm the clinical benefits, performance, and safety of this device by assessing how well it restores forefoot function at 3 to 4 months after surgery using the AOFAS-LMIS score. Participants receive treatment with the Lync4 intramedullary osteosynthesis device, which is implanted in the toes to address arthritis and bone alignment issues. The study monitors patients primarily at 3 to 4 months post-operation, with additional follow-ups if bone healing is incomplete. Secondary evaluations include pain reduction using the Visual Analogue Scale VAS, bone consolidation through radiographic exams, and monitoring for any adverse events or device defects throughout the study. During the study, participants will have clinical and radiographic assessments of their foot at 3 to 4 months after surgery, with an extra visit at 6 months if needed to confirm bone healing. Researchers will track pain levels, functional recovery, and safety outcomes, including any complications or device problems. The entire follow-up averages about 6 months, ensuring thorough monitoring of treatment effects and safety.

Researchers are studying advanced cancer of the stomach and the gastro-esophageal junction, a serious disease with low survival rates. The trial focuses on patients whose cancer has progressed after two or three prior treatments. The study aims to evaluate whether combining the oral drug trifluridinetipiracil with the anti-angiogenic drug fruquintinib can improve survival compared to trifluridinetipiracil alone. This international Phase III trial builds on recent advances in immunotherapy and targeted therapies for this cancer type. Participants are randomly assigned to one of two groups. One group receives trifluridinetipiracil alone in 28-day cycles, taking the drug by mouth twice daily on Days 1 to 5 and Days 8 to 12 with rest days in between, repeated every 4 weeks. The other group receives the same trifluridinetipiracil schedule plus fruquintinib by mouth once daily for 21 days each cycle. Treatment continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants undergo regular assessments to monitor overall survival up to 18 months after starting treatment. Researchers will also measure progression-free survival during this period. Patients will have tumor evaluations, laboratory tests, and monitoring for treatment side effects. Participants must meet specific health criteria and agree to biological studies. The study provides close follow-up to evaluate the effects of the treatments over time.